As shown in Figure 1A,B, patients with both EGFR-positive and HER2-positive breast cancer showed significantly poor disease-free survival (DFS, p = 0.0229) and overall survival (OS, p = 0.019) compared to patients with EGFR-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.